Lantheus Holdings won final FDA approval for BRAVNETSA, the first radiopharmaceutical the agency has cleared as bioequivalent and therapeutically equivalent to Novartis' LUTATHERA, opening a generic-style path into a market of roughly 200,000 U.S. patients.
"For more than 70 years, Lantheus has helped define what's possible in radiopharmaceuticals. As the first radioligand therapy approved through the ANDA pathway, BRAVNETSA represents a breakthrough for our industry and opens a new regulatory pathway for innovation," Ludger Dinkelborg, Head of Research and Development at Lantheus, said.
The approval, granted Sept. 22 through the FDA's Abbreviated New Drug Application pathway, covers lutetium Lu 177 dotatate for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut and hindgut tumors. Lantheus said BRAVNETSA is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product. The company did not disclose a launch date or list price, directing clinicians to a product site for availability timing.
Shares of the Bedford, Massachusetts-based company fell 0.5% to $100.27 in early trading, after closing at $100.28 on Sept. 21. The stock is up 50.6% year to date. Ten analysts covering the company carry a mean rating of outperform with an average target price of $107.74, implying 7.4% upside, according to MarketScreener consensus data.
The economics of the approval rest on substitution rather than new demand. Because the FDA found the two products interchangeable, BRAVNETSA can be dispensed against LUTATHERA prescriptions in the same way a generic competes with its brand — a structure that historically compresses price in the high single digits to low double digits within the first two years of launch. LUTATHERA is Novartis' only approved lutetium Lu 177 dotatate product in the United States, and the franchise has no other therapeutic equivalent on the market.
Lantheus is not disclosing revenue expectations for BRAVNETSA. The company suspended its previously issued full-year 2026 financial guidance on Aug. 6, the same day it reported second-quarter revenue of $388.2 million against a FactSet estimate of $363.2 million, and adjusted earnings of $1.55 per share against an estimate of $1.30.
The clinical case for the product is inherited from LUTATHERA's label. In the NETTER-1 trial, patients receiving lutetium Lu 177 dotatate with long-acting octreotide recorded anemia in 81% of cases versus 54% for high-dose octreotide alone, thrombocytopenia in 53% versus 17%, and neutropenia in 26% versus 11%. Platelet nadir occurred at a median of 5.1 months after the first dose. Myelodysplastic syndrome was reported in 2.3% of patients on the lutetium arm at a median follow-up of 76 months, against none in the comparator arm. In the ERASMUS study, 16 patients, or 2%, developed secondary myelodysplastic syndrome and four, or 0.5%, developed acute leukemia, with median onset at 29 months and 55 months respectively. Renal failure occurred in eight patients, fewer than 1%, between three and 36 months after treatment.
BRAVNETSA's label carries the same warnings as the reference product, including radiation exposure risk, myelosuppression, secondary malignancies, renal and hepatic toxicity, hypersensitivity reactions, neuroendocrine hormonal crisis, embryo-fetal toxicity and infertility risk. The recommended cumulative dose is 29.6 GBq. Pediatric use information is approved for LUTATHERA but is not on the BRAVNETSA label because of marketing exclusivity rights held by Novartis' Advanced Accelerator Applications unit.
The approval lands in the middle of a corporate transaction that has already reset how the market values Lantheus. Curium US LLC entered a definitive agreement on Aug. 3 to acquire Lantheus for $7 billion, and Curium resubmitted its antitrust filing for the merger, according to MarketScreener. B. Riley downgraded the stock to neutral from buy on Aug. 18 and cut its price target to $105.40 from $129, citing the Curium deal. That target sits below the $107.74 analyst average, and the spread between the two reflects disagreement over whether the merger price or standalone pipeline value should anchor the shares.
Lantheus has been adding to its portfolio on both sides of the diagnostic-therapeutic divide. The FDA approved Tauklarify, a florquinitau F 18 injection for Alzheimer's disease PET imaging, on Aug. 14. The company's commercial products include PYLARIFY for prostate cancer imaging, Neuraceq for Alzheimer's imaging and DEFINITY for ultrasound contrast, and it employs 1,193 people.
The competitive read-through extends beyond Novartis. Telix Pharmaceuticals agreed on Sept. 21 to buy Germany's ITM Isotope in a deal worth up to $2.35 billion, the latest sign that radiopharmaceutical manufacturing capacity is being consolidated as therapeutic demand grows. Lantheus' own supply and distribution network is named in its risk disclosures as a factor in whether it can commercialize BRAVNETSA reliably.
For holders, the approval converts Lantheus from a diagnostics company with a therapeutic option into a company with an approved radioligand therapy and a defined route to share gains against a branded incumbent. The next catalysts are the availability date for BRAVNETSA, which Lantheus has not set, and the antitrust review of the Curium acquisition, which will determine whether shareholders receive the $7 billion deal price or hold a standalone company whose therapeutic revenue is still unquantified.
This article is for informational purposes only and does not constitute investment advice.
